Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. - Wikidata - wikimedia - TriplyDB

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

http://www.wikidata.org/entity/Q33913556

about

Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth.Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.

P2860

Q34341837-7817DC32-1F77-4C5D-B2C8-EC1BEB867020 Q36223538-25E12C6B-32BF-4A20-B983-C1B9CD3D2894 Q38965801-5FBD99D1-8D51-4994-B37A-87268C4D3D71 Q39401943-7DC86E93-8635-4C60-8B94-BD73A89D79C2 Q40068276-7FB42F2F-1F1D-4824-ACE9-822AE80B8DE1 Q41889215-7F250EA7-05B8-4CBD-A706-DADEADBA28AA Q50019794-F3E2DA68-3105-4660-B785-DF3DC234AD05

P2860

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

http://www.wikidata.org/entity/Q33913556

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Modulation of circulating prot ...... patients with advanced cancer.

@ast

Modulation of circulating prot ...... patients with advanced cancer.

@en

type

label

Modulation of circulating prot ...... patients with advanced cancer.

@ast

Modulation of circulating prot ...... patients with advanced cancer.

@en

prefLabel

Modulation of circulating prot ...... patients with advanced cancer.

@ast

Modulation of circulating prot ...... patients with advanced cancer.

@en

P1433

Q33913556-DE7F8042-DC17-416A-BF29-FBF4F6309B05

P1476

Q33913556-58F72C33-9604-4B3E-8D6C-3AA23B4CF974

P2093

Q33913556-05AD1A69-EBA5-4A18-8539-522B15912D82

Q33913556-2E8A2117-7D6E-4483-9E59-11B1B6A17192

Q33913556-35CF94A5-0F79-426C-844A-BBB90969C42F

Q33913556-3CC52761-05B3-4242-B1CC-2DA01F39B8DA

Q33913556-58CABC3D-26E2-4DB3-B9EB-AC382E6EF142

Q33913556-7A57D5CC-F5DC-4E04-AC87-0C799BA119C3

Q33913556-82863FEC-56F6-45D3-863B-A881A753A8BB

Q33913556-A7D4D64D-A85D-4E35-8720-D3ADE9116579

Q33913556-B10E53EF-585D-4A4F-A438-3D04D8ECF5CE

P2860

Q33913556-011BACD0-5953-4ECE-8F11-B4AA7EB04F7B

Q33913556-035A2FC9-93D1-4063-851F-FD5E22172A82

Q33913556-0F4F114B-CDE3-426C-975A-C8D4C09BF2C2

Q33913556-1675F1E2-A93C-49B8-B7F6-A01AC76A8F0D

Q33913556-1869BB3E-721C-4683-A04B-1910DA197C5B

Q33913556-1AE1595B-3CBD-474B-86A0-79EB02A3C716

Q33913556-1F27CDA0-4519-46B2-A7DF-109A692BD93B

Q33913556-2867769A-A98A-4AFB-84FC-75B48E34FFCF

Q33913556-34E040EB-9CE2-4ECB-A11F-1E3C43968F89

Q33913556-382BC064-7B74-4FC2-BD80-B587D0F4FCD4

P304

Q33913556-796CC944-75F7-47FA-A334-C53BE90CD53D

P31

Q33913556-3052647F-6052-4630-BF17-C58D5CCCD7DA

P356

Q33913556-834CEA3B-8193-43C5-81B0-8B99B222764E

P407

Q33913556-41B5F922-4C38-4370-A9EF-24E590F712F8

P433

Q33913556-9FDA6EC6-5FB4-455B-893D-CACB890A52FC

P478

Q33913556-81EEF067-ADEA-4DE6-A660-9E6015B4B243

P50

Q33913556-64254336-42D5-42B3-80BA-F9525D42FF43

P577

Q33913556-D69AE6D2-0F05-4209-85C0-212EE92AFC62

P5875

Q33913556-E0728D61-98A5-46C9-A1B2-99438FB8AC3E

P698

Q33913556-6FC641D9-CFFE-4B65-8803-457956E10EDE

P921

Q33913556-086EC1CC-5DD0-4271-8245-CD4446354F9A

P932

Q33913556-543EB436-6BCF-49F0-BB5C-F0C488768AD0

P356

P1433

Cancer Medicine

P1476

Modulation of circulating prot ...... patients with advanced cancer

@en

P2093

Andrew B Nixon

http://www.w3.org/2001/XMLSchema#string

Andrew Dellinger

http://www.w3.org/2001/XMLSchema#string

Bonne Adams

http://www.w3.org/2001/XMLSchema#string

Charles P Theuer

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

John C Brady

http://www.w3.org/2001/XMLSchema#string

Mark D Starr

http://www.w3.org/2001/XMLSchema#string

Nam Y Lee

http://www.w3.org/2001/XMLSchema#string

Yingmiao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Matricellular proteins: a sticky affair with cancers

Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells

Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

Angiopoietins in malignancy.

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.

Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells.

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.

Vascular endothelial growth factor and the regulation of angiogenesis.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)

P304

580-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.207

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260396620

http://www.w3.org/2001/XMLSchema#string

P698

24574330

http://www.w3.org/2001/XMLSchema#string

P921

P932

4101749

http://www.w3.org/2001/XMLSchema#string